Form 4: EyePoint Pharmaceuticals Director Nancy Lurker Reports Stock Transactions
SEC Form 4
Director Nancy Lurker reports acquisition and disposal of EyePoint Pharmaceuticals stock and derivative securities.
Summary
- On January 3, 2025, Nancy Lurker, a director of EyePoint Pharmaceuticals, acquired 40,000 stock options with an exercise price of $8.26, expiring on January 3, 2035.
- On January 5, 2025, Lurker converted 12,667 restricted stock units into common stock.
- Following this transaction, Lurker directly owns 110,302 shares of common stock.
- On January 6, 2025, Lurker converted 75,134 restricted stock units into common stock.
- Following this transaction, Lurker directly owns 185,436 shares of common stock.
- Lurker also indirectly owns 126,889 shares through a family trust.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions; it doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Acquisition of 40,000 stock options. |
| 01/05/2025 | Conversion of 12,667 restricted stock units to common stock. |
| 01/06/2025 | Conversion of 75,134 restricted stock units to common stock. |
| 01/07/2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.